Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report.

Dehning J, Grunze H, Hausmann A.

Clin Pract Epidemiol Ment Health. 2017 May 31;13:43-48. doi: 10.2174/1745017901713010043. eCollection 2017.

2.

The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Fountoulakis KN, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller HJ.

Int J Neuropsychopharmacol. 2017 Feb 1;20(2):121-179. doi: 10.1093/ijnp/pyw100.

3.

Management of bipolar disorder in the intercontinental region: an international, multicenter, non-interventional, cross-sectional study in real-life conditions.

Samalin L, Vieta E, Okasha TA, Uddin MJ, Ahmadi Abhari SA, Nacef F, Mishyiev V, Aizenberg D, Ratner Y, Melas-Melt L, Sedeki I, Llorca PM.

Sci Rep. 2016 May 16;6:25920. doi: 10.1038/srep25920.

4.

Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.

Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ.

Br J Psychiatry. 2016 Apr;208(4):359-65. doi: 10.1192/bjp.bp.115.169375. Epub 2016 Feb 18.

5.

Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.

Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ.

Acta Psychiatr Scand. 2016 Jun;133(6):459-69. doi: 10.1111/acps.12557. Epub 2016 Jan 24.

6.

Antidepressants in Type II Versus Type I Bipolar Depression: A Randomized Discontinuation Trial.

Vöhringer PA, Ostacher MJ, El-Mallakh RS, Holtzman NS, Thommi SB, Whitham EA, Sullivan MC, Baldassano CF, Goodwin FK, Baldessarini RJ, Ghaemi SN.

J Clin Psychopharmacol. 2015 Oct;35(5):605-8. doi: 10.1097/JCP.0000000000000384.

7.

Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study.

Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ.

J Affect Disord. 2015 Oct 1;185:31-7. doi: 10.1016/j.jad.2015.05.070. Epub 2015 Jun 26.

8.

Review of evidence for use of antidepressants in bipolar depression.

McInerney SJ, Kennedy SH.

Prim Care Companion CNS Disord. 2014 Oct 16;16(5). doi: 10.4088/PCC.14r01653. eCollection 2014. Review.

9.

Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis.

Severus E, Taylor MJ, Sauer C, Pfennig A, Ritter P, Bauer M, Geddes JR.

Int J Bipolar Disord. 2014 Dec 20;2:15. doi: 10.1186/s40345-014-0015-8. eCollection 2014.

10.

Antidepressants for bipolar disorder: A meta-analysis of randomized, double-blind, controlled trials.

Zhang Y, Yang H, Yang S, Liang W, Dai P, Wang C, Zhang Y.

Neural Regen Res. 2013 Nov 5;8(31):2962-74. doi: 10.3969/j.issn.1673-5374.2013.31.009.

11.

The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.

Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, Goodwin GM, Sachs GS, Tondo L, Findling RL, Youngstrom EA, Tohen M, Undurraga J, González-Pinto A, Goldberg JF, Yildiz A, Altshuler LL, Calabrese JR, Mitchell PB, Thase ME, Koukopoulos A, Colom F, Frye MA, Malhi GS, Fountoulakis KN, Vázquez G, Perlis RH, Ketter TA, Cassidy F, Akiskal H, Azorin JM, Valentí M, Mazzei DH, Lafer B, Kato T, Mazzarini L, Martínez-Aran A, Parker G, Souery D, Ozerdem A, McElroy SL, Girardi P, Bauer M, Yatham LN, Zarate CA, Nierenberg AA, Birmaher B, Kanba S, El-Mallakh RS, Serretti A, Rihmer Z, Young AH, Kotzalidis GD, MacQueen GM, Bowden CL, Ghaemi SN, Lopez-Jaramillo C, Rybakowski J, Ha K, Perugi G, Kasper S, Amsterdam JD, Hirschfeld RM, Kapczinski F, Vieta E.

Am J Psychiatry. 2013 Nov;170(11):1249-62. doi: 10.1176/appi.ajp.2013.13020185.

12.

The prevalence of bipolar disorder in primary care patients with depression or other psychiatric complaints: a systematic review.

Cerimele JM, Chwastiak LA, Dodson S, Katon WJ.

Psychosomatics. 2013 Nov-Dec;54(6):515-24. doi: 10.1016/j.psym.2013.05.009. Epub 2013 Aug 9. Review.

13.

The presentation, recognition and management of bipolar depression in primary care.

Cerimele JM, Chwastiak LA, Chan YF, Harrison DA, Unützer J.

J Gen Intern Med. 2013 Dec;28(12):1648-56. doi: 10.1007/s11606-013-2545-7. Review.

14.

Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder.

Amsterdam JD, Luo L, Shults J.

Br J Psychiatry. 2013 Apr;202(4):301-6. doi: 10.1192/bjp.bp.111.104711. Epub 2012 Oct 25.

15.

Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP.

Haeberle A, Greil W, Russmann S, Grohmann R.

BMC Psychiatry. 2012 Sep 21;12:153. doi: 10.1186/1471-244X-12-153.

16.
17.
18.

Broadening the diagnosis of bipolar disorder: benefits vs. risks.

Strakowski SM, Fleck DE, Maj M.

World Psychiatry. 2011 Oct;10(3):181-6.

19.

Primary care perspectives on treating bipolar disorder: a cross-sectional survey.

Sansone RA, Forbis JS, Sosa T.

Prim Care Companion CNS Disord. 2011;13(2). pii: PCC.10m01072. doi: 10.4088/PCC.10m01072.

20.

Stuck in a rut: rethinking depression and its treatment.

Holtzheimer PE, Mayberg HS.

Trends Neurosci. 2011 Jan;34(1):1-9. doi: 10.1016/j.tins.2010.10.004. Epub 2010 Nov 8.

Supplemental Content

Support Center